{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:54:12Z","timestamp":1791255252765,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cjca.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:09:02Z","timestamp":1776726542000},"page":"2299-2309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiovascular Outcomes With GLP-1 Receptor Agonists in Patients With Diabetes or Obesity Undergoing Transcatheter Aortic Valve Replacement"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8062-5657","authenticated-orcid":false,"given":"Aman","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humza","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hritvik","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Hurjkaliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauranga","family":"Mahalwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikash","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval","family":"Kolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2026.04.003_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jcmg.2023.02.018","article-title":"Prevalence of aortic valve calcium and the long-term risk of incident severe aortic stenosis","volume":"17","author":"Whelton","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2026.04.003_bib2","first-page":"e35","article-title":"2020 ACC\/AHA Guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.04.003_bib3","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jcin.2024.12.016","article-title":"Temporal trends in 1-year cause-specific mortality after TAVR: insights from the STS\/ACC TVT registry","volume":"18","author":"Kolte","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2026.04.003_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036657","article-title":"Clinical outcomes according to aortic stenosis management: insights from real-world practice","volume":"13","author":"Coisne","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2026.04.003_bib5","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jamacardio.2024.3453","article-title":"Trends in transcatheter aortic valve replacement outcomes: insights from the STS\/ACC TVT registry","volume":"9","author":"Arnold","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2026.04.003_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.117.005417","article-title":"Clinical impact of diabetes mellitus on outcomes after transcatheter aortic valve replacement: insights from the Society of Thoracic Surgeons\/American College of Cardiology Transcatheter Valve Therapy Registry","volume":"10","author":"Abramowitz","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2026.04.003_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.mayocp.2019.09.027","article-title":"Relationship of body mass index with outcomes after transcatheter aortic valve replacement: results from the National Cardiovascular Data-STS\/ACC TVT Registry","volume":"95","author":"Sharma","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cjca.2026.04.003_bib8","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.04.003_bib9","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.04.003_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.cjca.2026.04.003_bib12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ehjqcco\/qcaf135","article-title":"GLP-1 receptor agonists and clinical outcomes in patients with type 2 diabetes undergoing transcatheter aortic valve implantation","volume":"12","author":"Pham","year":"2026","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.cjca.2026.04.003_bib13","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jacasi.2025.06.012","article-title":"Body mass index and outcomes after transcatheter aortic valve replacement","volume":"5","author":"Cantey","year":"2025","journal-title":"JACC Asia"},{"key":"10.1016\/j.cjca.2026.04.003_bib14","first-page":"565","article-title":"Effect of elevated body mass index on outcomes of transcatheter aortic valve replacement for severe aortic stenosis","volume":"28","author":"Yamashita","year":"2024","journal-title":"Anatol J Cardiol"},{"key":"10.1016\/j.cjca.2026.04.003_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.04.003_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2026.04.003_bib17","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-\/- and LDLr-\/- mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cjca.2026.04.003_bib18","doi-asserted-by":"crossref","first-page":"16489","DOI":"10.1096\/fj.202000860RR","article-title":"Incretin drugs effect on epigenetic machinery: new potential therapeutic implications in preventing vascular diabetic complications","volume":"34","author":"Scisciola","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.cjca.2026.04.003_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13216411","article-title":"Effect of glucagon-like peptide-1 receptor agonism on aortic valve stenosis risk: a Mendelian randomization analysis","volume":"13","author":"Karakasis","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.cjca.2026.04.003_bib20","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2026.04.003_bib21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/dc24-1533","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2026.04.003_bib22","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2026.04.003_bib23","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.21037\/cdt-20-916","article-title":"Long term mortality and readmissions after transcatheter aortic valve replacement","volume":"11","author":"Senussi","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.cjca.2026.04.003_bib24","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.cjca.2026.04.003_bib25","doi-asserted-by":"crossref","first-page":"F1010","DOI":"10.1152\/ajprenal.00028.2019","article-title":"Does glucagon-like peptide-1 induce diuresis and natriuresis by modulating afferent renal nerve activity?","volume":"317","author":"Katsurada","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.cjca.2026.04.003_bib26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jcin.2022.01.018","article-title":"New-onset atrial fibrillation after transcatheter aortic valve replacement: a systematic review and meta-analysis","volume":"15","author":"Ryan","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2026.04.003_bib27","doi-asserted-by":"crossref","unstructured":"Cesaro A, Pastori D, Acerbo V, et al. Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials [e-pub ahead of print]. Eur J Prev Cardiol https:\/\/doi.org\/10.1093\/eurjpc\/zwaf257.","DOI":"10.1093\/eurjpc\/zwaf257"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26003582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26003582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:43:49Z","timestamp":1791254629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X26003582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0828282X26003582"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2026.04.003","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Outcomes With GLP-1 Receptor Agonists in Patients With Diabetes or Obesity Undergoing Transcatheter Aortic Valve Replacement","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2026.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}